Fetal Bovine Serum Market By Application(Cell-based research, Vaccine production , Diagnostics, Drug discovery, Toxicity testing, In-vitro fertilization, Cell therapy), By End-User(Pharmaceuticals and Biotechnology Industries, Academic Institutes, Research labs, Diagnostic labs, IVF centers), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
-
42624
-
Dec 2023
-
179
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Fetal Bovine Serum Market Size, Share, Trends Analysis
The fetal bovine serum market was valued at USD 2.9 billion in 2023. It is expected to reach USD 12.9 billion by 2033, with a CAGR of 16.5% during the forecast period from 2024 to 2033.
The surge in demand for acute and chronic lung disease treatment and advances in R&D are some of the main major factors for fetal bovine serum market expansion. Fetal bovine serum is also known as FBS or fetal calf serum, which is used widely by medical and industrial researchers as a supplement in cell culture application through basal growth medium.
FBS is a rich source of protein and a development factor that supports cell growth culture. It is one of the general serums that are used, however, the serum is dependent upon the chemical composition of basal media, the type of cell growth, and the purpose of the experiment.
Fetal bovine serum is appropriate in the fields of biotechnology, biology, medical research, and diagnosis of disease. It has a large amount of albumin that is needed for cell proliferation, especially for eukaryotic cells. It is a natural media through which medical researchers can alter and use as per their needs. Many industries such as research, academics, and the diagnosis sector are using FBS for tissue culture experiments. FBS enhances value as it has rich nutrients.
FBS offers a rich culture system that can assist various ranges of cell types, comprising cell lines and primary cells. The low levels of antibodies and growth factors in FBS simplify the usefulness of this serum. It has 1000 varieties of components such as lipids, hormones, enzymes, carriers, electrolytes, and other sources of energy that are needed for cell growth.
There are several reasons to opt for FBS such as it is the proven media for processing the eukaryotic cell culture. It has less gamma globulin and more fetal albumin than any other natural and organic media.
For vaccine production, FBS is used as an ingredient in the cultural media to produce new and transformed bacterial cell attachment. In biotechnology research, FBS acts as the media for the biotechnology cell culture, which provides solid stability, proliferation, and nutrients. FBS is used for cancer research as, according to the American Cancer Society, 1,958,310 new cancer cases have been reported, and among that 609,820 are death cases caused by cancer in 2023 in the US.
Fetal bovine serum is an exceptional source of nutrients in animal cell culture and basal cell culture. Currently, there are several ready-to-use culture media due to which the demand for the FBS will increase and help in market expansion in the coming years.
Fetal Bovine Serum Market Dynamics
Research Needs Fuel Fetal Bovine Serum Demand
The expanding need for scientific research and industrial production is significantly driving the fetal bovine serum (FBS) market. FBS is a critical component in in-vitro cell culture, essential for scientific research, particularly in microbiology and immunology.
Cell culture research, biotechnology development, and vaccine production have driven an upsurge in demand for top-quality FBS. As research expands into areas like biotechnology and life sciences, FBS as an integral component of culture media is likely to become even more essential, driving market growth forward.
Disease Prevalence Spurs Market Growth
Due to rising incidences of disease and chronic health issues globally, FBS is becoming a vital asset in medical research for drug development as well as toxicology testing, providing essential clues in diagnosing and treating ailments.
With chronic and infectious diseases on the rise, there is an ever-increasing need for research and development efforts that make FBS essential. This key trend is expected to persist and increase accordingly, necessitating more use of FBS for research into medical conditions as well as disease studies.
Biopharmaceutical Growth in Developing Nations
Fetal Bovine Serum market growth is expanding quickly across many nations due to their expanding biopharmaceutical sectors and due to investments made into healthcare infrastructure as well as an increase in R&D within life sciences, as well as rising biopharmaceutical demands - factors which are fueling market expansion for this biopharmaceutical industry.
As developing countries invest more research dollars into biotech and research, their need for high-quality bovine fetal serum - an essential element of cell culture medium - continues to rise steadily. Cell culture is integral to producing therapeutic proteins, vaccines, and other biopharmaceuticals such as vaccines.
Scientific and Ethical Concerns Limit Fetal Bovine Serum Market Growth
The Bovine Fetal Serum (FBS) market is experiencing significant restrictions due to research and ethical considerations. FBS is widely used as an ingredient for cell culture mediums; however, its production from pregnant cows that were killed raises ethical concerns regarding animal welfare.
These ethical concerns have drawn the scrutiny of regulatory agencies as well as scientific communities and the general public, prompting an effort towards more ethical and compassionate alternatives. Variations in FBS composition could even have an impact on scientific research results - further emphasizing the need for standardized ethically sourced alternatives.
Limited Production Capacity and Increasing Demand Challenge Fetal Bovine Serum Market
Fetal bovine serum production capacity has become inadequate to keep pace with demand, creating difficulties for its market. FBS production is limited due to it being an end product from the meat industry; availability depends on changes in that sector of the industry.
As demand for FBS grows in pharmaceuticals, biomedical research, and other life science applications, its supply is struggling to keep up with market demands. This imbalance between demand and supply leads to higher prices as well as possible shortages, making it hard for manufacturers and researchers to rely on FBS as a reliable resource - further impeding market trends expansion and stability.
Fetal Bovine Serum Market Segmentation Analysis
By Application Analysis
In the fetal bovine serum market, vaccine production emerges as the dominant segment. FBS plays an essential role in vaccine research and production, particularly as an embryonic growth-promoting factor source. With global efforts underway to combat infectious diseases such as the COVID-19 pandemic spreading worldwide, its growth is becoming ever more dramatic.
Fetal bovine serum can also be used for cell research, diagnostics, drug discovery services, and testing for toxicity; in-vitro fertilization as well as cell therapy treatments are among other uses of this material. In cell-based research, FBS is utilized for cultivating cells under in-vitro conditions.FBS is used in diagnostics and drug discovery industries to develop and test new diagnostic and therapeutic approaches, assess toxicity testing of chemical and pharmaceutical substances, facilitate in vitro fertilization processes as well as cell therapy treatments, promote cell growth and development, and aid cell therapy treatments.
By End-User Analysis
FBS is widely utilized by both biotech and pharmaceutical sectors as a key ingredient for drug development, manufacturing processes, research activities, and other research processes. FBS plays an integral role in these activities due to increasing investments by pharmaceutical corporations into R&D, rising biopharmaceutical demand as well as biotech industry growth; FBS plays an essential role in cell culture for research and production activities as a result. Its growth can be explained by this fact alone.
Pharmaceutical and biotechnology industries universities research labs universities diagnostic labs IVF centers and more all use Fetal Bovine Serum (FBS). Academic institutions often utilize FBS for research and education; diagnostic labs use FBS in various tests; while IVF centers also frequently incorporate it when conducting reproductive techniques and procedures with FBS as a key part. All this contributes to an ever-increasing demand for Fetal Bovine fetuses serum.
Fetal Bovine Serum Industry Segments
By Application
- Cell-based research
- Vaccine production
- Diagnostics
- Drug discovery
- Toxicity testing
- In-vitro fertilization
- Cell therapy
By End-User
- Pharmaceuticals and Biotechnology Industries
- Academic Institutes
- Research labs
- Diagnostic labs
- IVF centers
Fetal Bovine Serum Market Growth Opportunity
Expansion of Pharmaceutical, Biotechnology, and Veterinary Industries Spurs Fetal Bovine Serum Market Growth
FBS (Fractionated Bovine Serum) market growth is being fuelled by biotechnology, pharmaceutical, and veterinary businesses as it plays a crucial role in cell culture media for drug development, biotech studies, and applications within veterinary medicine. FBS plays an integral part in cell culture media formulation.
As these industries grow and their research and development activities increase, the demand for high-quality FBS also rises. The expansion of these sectors, driven by the constant pursuit of new medical and biotechnological advancements, underlines a robust market expansion for FBS as an essential resource for various research and production processes.
Increasing Application in Drug Discovery and Vaccine Production Boosts Fetal Bovine Serum Market
Fetal Bovine Serum (FBS) market growth can be attributed to its growing use in vaccine and drug discovery processes, and in vitro tests using FBS as well as screening compounds that could potentially be utilized for pharmaceutical research.
Moreover, FBS has played an increasing role in producing vaccines, particularly given the recent surge in vaccine research. FBS plays an essential role in this area; combined with an increased focus on creating new medications and vaccines for development purposes, this represents a tremendous growth opportunity as demand for reliable serum rises steadily across pharmaceutical and biotech industries.
Fetal Bovine Serum Market Regional Analysis
North America Dominates with 35.00% Market Share in Fetal Bovine Serum Market
North America represents 35.00% of the fetal bifida serum (FBS) market due to the presence of large pharmaceutical and biotechnology industries that utilize FBS for research and production purposes. Particularly notable is that America boasts numerous biomedical research facilities, biotech firms, pharmaceutical firms, and biotech firms that require top-quality FBS for cell culture procedures and other biotechnological processes. Furthermore, advanced agricultural practices and an established livestock industry ensure a constant supply of bovine by-products across North America.
North America is home to stringent quality control standards and regulations governing animal-derived products that ensure reliability and safety, such as FBS. Furthermore, leading suppliers and manufacturers contribute to an effective infrastructure and supply chain; ongoing life sciences research as well as increasing investment in biotechnology R&D activities fuel demand for high-grade FBS.
Europe: Stringent Regulatory Environment and High-Quality Standards
European markets for fetal bovine saline (FBS) are driven by rigorous regulations and quality standards, with biotechnology and pharmaceutical industries and animal-derived product regulations contributing significantly to an expansion in FBS consumption. A key driver in terms of market dynamics may also include ethical sourcing practices as a focus in Europe's FBS supply chains.
Asia-Pacific: Rapidly Growing Biotech Sector and Increased R&D Activities
Asia-Pacific's FBS market is experiencing rapid growth, driven by an expanding biotech sector and increased R&D activities in countries like China, India, and Japan. Rising investments in life sciences research combined with increasing demands for cell culture media contribute to this rapid expansion. Asia-Pacific's emerging biotechnology landscape and rising role in global pharmaceutical production present numerous opportunities for the FBS market to flourish.
Fetal Bovine Serum Industry By Region
North America
- US
- Canada
- Mexico
Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Fetal Bovine Serum Market Share Analysis
In the Fetal Bovine Serum (FBS) Market, an essential segment for biomedical research and biotechnology, the major companies listed are key players influencing the industry's dynamics. Danaher (Cytiva) and Merck KGaA (Sigma Aldrich) are leading suppliers, known for their high-quality serum products essential for cell culture applications. Their strategic positioning emphasizes consistent quality and reliability, which are critical in research settings.
HiMedia Laboratories Pvt. Ltd and Bio-Techne are significant for their specialized offerings in cell culture and life sciences, reflecting the market's focus on supporting diverse research needs. Sera Scandia (Biowest) and Sartorius (Biological Industries) contribute to the market with their range of serum products, catering to the specific requirements of scientific research in pharmaceuticals and biotechnology companies.
Atlas Biologicals and Rocky Mountain Biologicals, while smaller in scale compared to the global giants, provide niche solutions and have established themselves as reliable sources in the FBS market. PAN-Biotech and Thermo Fisher Scientific Inc. recognized for their broad life sciences portfolios, play crucial roles in the market, offering a wide array of products and services that support biomedical research and bioprocessing.
Fetal Bovine Serum Industry Key Players
- Danaher (Cytiva)
- Merck KGaA (Sigma Aldrich)
- HiMedia Laboratories Pvt. Ltd
- Bio-Techne
- Sera Scandia (Biowest)
- Sartorius (Biological Industries)
- Atlas Biologicals
- Rocky Mountain Biologicals
- PAN-Biotech
- Thermo Fisher Scientific Inc.
- Bovogen Biologicals Pty Ltd
Fetal Bovine Serum Market Recent Development
- In August 2023, Omeat launched "Plenty," a potent and cost-effective replacement for fetal bovine serum (FBS). This development aimed to improve price points for cultivated meat production.
- In 2023, Clever Carnivore, a biotech startup, secured $7 million in seed round funding to expand its low-cost cultivated pork sausage production. This funding indicates growing interest and investment in the cultivated meat sector, which often relies on FBS for cell culture.
- In September 2022, Scientists from the National University of Singapore (NUS) developed a novel technique to grow cell-based meat using magnetic fields. This innovative method reduces reliance on animal products, making it a greener, cleaner, safer, and more cost-effective way to produce cultured meat.
- In 2022, General Mills planned to launch their Bold Cultr line of cow-free dairy products using lab-made dairy proteins from Perfect Day, a company specializing in cow-free dairy proteins.
Report Scope
Report Features Description Market Value (2023) USD 2.9 Billion Forecast Revenue (2033) USD 12.9 Billion CAGR (2024-2032) 16.5% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Application(Cell-based research, Vaccine production , Diagnostics, Drug discovery, Toxicity testing, In-vitro fertilization, Cell therapy), By End-User(Pharmaceuticals and Biotechnology Industries, Academic Institutes, Research labs, Diagnostic labs, IVF centers) Regional Analysis North America – The US, Canada, Mexico, Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America, Eastern Europe – Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe, Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe, APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC, Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA Competitive Landscape Danaher (Cytiva), Merck KGaA (Sigma Aldrich), HiMedia Laboratories Pvt. Ltd, Bio-Techne, Sera Scandia (Biowest), Sartorius (Biological Industries), Atlas Biologicals, Rocky Mountain Biologicals, PAN-Biotech, Thermo Fisher Scientific Inc., Bovogen Biologicals Pty Ltd Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
-
- Danaher (Cytiva)
- Merck KGaA (Sigma Aldrich)
- HiMedia Laboratories Pvt. Ltd
- Bio-Techne
- Sera Scandia (Biowest)
- Sartorius (Biological Industries)
- Atlas Biologicals
- Rocky Mountain Biologicals
- PAN-Biotech
- Thermo Fisher Scientific Inc.
- Bovogen Biologicals Pty Ltd